← All trials
NCT02885857
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2015
- Primary completion
- Dec 1, 2016
- Completion date
- Dec 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 1500
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- People's Liberation Army of ChinaLead sponsor
- Heilongjiang University of Traditional Chinese MedicineOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Shanxi Medical UniversityOverall official - principal investigator
- China Academy of Chinese Medical SciencesOverall official - principal investigator
- Jilin UniversityOverall official - principal investigator
- Tianjin University of Traditional Chinese MedicineOverall official - principal investigator
- Shaanxi University of Chinese MedicineOverall official - principal investigator
- Tianjin TongRenTang Group Co., Ltd.Collaborator
- People's Liberation Army of ChinaSponsor investigator
- People's Liberation Army of ChinaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.